The ability of DCF to deplete MDSC in some patients while generating hTERT restricted TH1 immune response established the rational to combine this chemotherapy with PD-1 neutralization by an inhibitor of PD-L1 in HPV-driven cancers. The gene discussed is CD274; the disease is cancer.